Contineum Therapeutics (CTNM) Assets Average: 2024-2025
Historic Assets Average for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $186.9 million.
- Contineum Therapeutics' Assets Average fell 14.55% to $186.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.9 million, marking a year-over-year decrease of 14.55%. This contributed to the annual value of $171.6 million for FY2024, which is N/A change from last year.
- As of Q3 2025, Contineum Therapeutics' Assets Average stood at $186.9 million, which was down 1.95% from $190.6 million recorded in Q2 2025.
- Contineum Therapeutics' 5-year Assets Average high stood at $218.7 million for Q3 2024, and its period low was $127.0 million during Q1 2024.
- In the last 2 years, Contineum Therapeutics' Assets Average had a median value of $190.6 million in 2025 and averaged $187.9 million.
- Over the last 5 years, Contineum Therapeutics' Assets Average had its largest YoY gain of 61.89% in 2025, and its largest YoY loss of 14.55% in 2025.
- Over the past 2 years, Contineum Therapeutics' Assets Average (Quarterly) stood at $214.4 million in 2024, then decreased by 14.55% to $186.9 million in 2025.
- Its Assets Average stands at $186.9 million for Q3 2025, versus $190.6 million for Q2 2025 and $205.6 million for Q1 2025.